Insulin Glargine and Risk of Cancer: A Meta-Analysis

Aims Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Here we strived to estimate the association of cancer occurrence with the use of insulin glargine. Methods We searched all the publications regarding the association between cancer occurrence and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The International journal of biological markers 2012-07, Vol.27 (3), p.241-246
Hauptverfasser:	Du, Xinli, Zhang, Rihua, Xue, Yi, Li, Dong, Cai, Jinmei, Zhou, Suming, Huang, Zhengkai, Yu, Rongbin, Liu, Yun
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Cohort Studies Diabetes Mellitus, Type 2 - drug therapy Female Humans Hypoglycemic Agents - administration & dosage Insulin Glargine Insulin, Long-Acting - administration & dosage Male Middle Aged Neoplasms - epidemiology Neoplasms - prevention & control Risk
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Here we strived to estimate the association of cancer occurrence with the use of insulin glargine. Methods We searched all the publications regarding the association between cancer occurrence and the use of insulin glargine using the US National Library of Medicine's PubMed database. Data were independently extracted and analyzed using random or fixed effects meta-analysis depending upon the degree of heterogeneity. Results Seven cohort studies were included in the meta-analysis. Cancer occurrence had no significant difference in glargine-treated patients compared to patients treated with other insulins (RR=0.86, 95% CI=0.69–1.07, p=0.17, Pheterogeneity
ISSN:	0393-6155 1724-6008
DOI:	10.5301/JBM.2012.9349